Ticker: APLS

APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) is currently navigating a complex financial landscape characterized by significant revenue fluctuations and rising operational costs. Key Points from the Income Statement: Q2 2025 Product Revenue: $171.4 million, a decrease of 4% from $179.1 million i...